Marieke E.C. van Winden, Elke L.M. ter Haar, Hans M.M. Groenewoud, Peter C.M. van de Kerkhof, Elke M.G.J. de Jong, Satish F.K. Lubeek
DOI: 10.2340/00015555-3569

Little is known about psoriasis in geriatric patients, whereas treating this growing population can be challenging due to comorbidities, comedication and physical impairments. To compare disease and treatment characteristics of psoriasis patients ≥ 65 years old with patients < 65 years old, a self-assessment survey was sent to all members of the Dutch Psoriasis Association (n = 3,310). In total, 985 (29.7%) patients returned the survey, 414 (43.6%) respondents were ≥ 65 years old. Patients ≥ 65 years old had experienced erythrodermic psoriasis significantly more frequently than patients < 65 years old, other disease characteristics were highly comparable. Despite a significantly higher prevalence of comorbidities and comedication use in patients ≥ 65 years old, no difference was seen between the age groups regarding systemic antipsoriatic treatment (38.3% in ≥ 65 years old vs 42.3% in < 65 years old; p = 0.219). Remarkably, treatment-related side-effects were reported more frequently by patients < 65 years old. In conclusion, age alone should not be a limiting factor in psoriasis management, and proper attention must be paid to additional patient-related factors.

Little is known about geriatric psoriasis, although health problems and medication can complicate the management of psoriasis. To compare characteristics of patients ≥ 65 years old with those < 65 years old, a survey was sent to all members (3,310) of the Dutch Psoriasis Association. In total, 985 (29.7%) patients returned the survey, 414 (43.6%) respondents were ≥ 65 years old. Despite more comorbidities and medication use in ≥ 65 years old, no difference was seen between age groups regarding systemic antipsoriatic treatment (38.3% vs 42.3%). Side-effects were reported more frequently by patients < 65 years old. Thus, age alone should not limit psoriasis treatment, and proper attention must be paid to patient-related factors.

Table SI
Figure S1
Table SII
Table SIII
Figure S2
Figure S3